02 April 2020 | News
To monitor and validate COVID-19 molecular diagnostic tests
Image credit- shuttershock.com
Thermo Fisher Scientific, the world leader in serving science, has announced the availability of the Thermo Scientific AcroMetrix Coronavirus 2019 (COVID-19) RNA Control, its latest quality control product to monitor and validate COVID-19 molecular diagnostic tests.
In an effort to combat the recent Coronavirus outbreak, Thermo Fisher designed and developed this control as a synthetic RNA, non-infectious control to help labs validate and monitor COVID-19 molecular diagnostic tests. Taking FDA guidelines into account, the controls were carefully designed at two different concentrations: a low positive control and an ultra-low positive control.
AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is prepared by formulating synthetic RNA transcripts that contain highly unique N, S, E and Orf1ab regions of SARS-CoV-2 (COVID-19) genome into a proprietary buffer. The RNA is ready for reverse transcription, PCR amplification and detection, as appropriate to the test. The kit contains two vials of SARS-CoV-2 specific RNA at the concentration that will result low positive and ultra-low positive in most commonly used Polymerase Chain Reaction (PCR) based Coronavirus 2019 (COVID-19) nucleic acid testing methods.